


Axio Biosolutions attains world class position

24 April 2019 | News

The Bengaluru-based medtech company expands its state-of-the-art manufacturing facility at Gujarat Pharma Techno Park in Ahmedabad



India's leading innovative medtech company, Axio Biosolutions, recently expanded its state-of-the-art manufacturing facility at Gujarat Pharma Techno Park in Ahmedabad, India to over a million units annually and has become the largest chitosan medical sponge manufacturer globally.

As the first-ever Indian company to design and launch a novel haemostat for moderate to severe bleeding, Axio Biosolutions has been consistently disrupting the wound care management industry. Its manufacturing facility is ISO 13485 certified and GMP approved, with an ISO 7, Class 10000 cleanroom. Now, with the cutting-edge factory that is 75 per cent automated, boosting the annual capacity to over a million units, the company is all set to conquer new frontiers.

Commenting on the latest development, Gourav Maheshwari, Director – Finance & Operations, said, "Our products are proudly made in India for the global market. With this expansion along with USFDA clearance for our products we are closer to realising our aspirations to become a global medtech company from India. We have created more than 100 jobs for local community with a significant contribution of women staff, we believe this facility will set a benchmark for medtech manufacturing in India."

Axio Biosolutions is a medtech company with focus on biomaterials. The company offers a complete range of innovative products spanning pre-hospital, intra-operative and post-operative clinical needs. Its first product range Axiostat is a USFDA and CE approved product that stops bleeding instantly. Earlier this year, the company launched MaxioCel, a next-generation, chitosan-based advanced wound care dressing that provides comfort and faster healing to patients suffering from chronic wounds.

Axio Biosolutions recently announced its top-notch Scientific Advisory Board, comprising Dr Shiladitya Sengupta, Assistant Professor of Medicine at Harvard Medical School, as Chairman and Dr S V Mahadevan, Professor of Emergency Medicine at

Stanford University, as member.

Last year, the company raised \$7.4 million in a Series B funding round led by Ratan Tata's UC- RNT, along with existing investors Accel Partners and IDG Ventures India.

Headquartered in Cambridge, Axio Biosolutions has its corporate office in Bengaluru. The company has strong R&D with multiple patents to its credit.